Introduction: As a reason for hearing disorders by patients with thalassemic syndromes arc underlined the ototoxicity of deferoxamine in the therapy of the thalassemia.
Objective: The aim of the study is to establish the presence of hearing disorders by patients with thalassemic syndromes under regular haemotransfusions and chelating therapy.
Study design: Multicentre prospective research - ENT Clinic, Paediatric Clinic, Therapeutic Clinic, Medicine Faculty, Stara Zagora; 6-th Therapeutic Department, District Hospital "Prof. S. Kirkovich", Stara Zagora; Sector of Thalassemia, Paediatric Hospital, Sofia; Sector of Thalassemia, National Centre of Transfusiology, Sofia.
Material and Methods: 63 patients with beta-thalassemia under regular hacmotransfusions and chelating therapy were examinated. For the assessment of the hearing function were used otoacoustic emissions, audiometry and brainstem evoked potentials.
Results: By 15 patients with thalassemic syndromes (23.81 %) were registreted abnormal audiogram's - neurosensorial hearing disorder. By 4 of them the hearing disorder was combining.
Disscusion: Our results by assessment of the hearing function arc not so different of the results in the studies of many authors.
Ambrosеtti U, Donde E, Piatti G, Cappellini MD. Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment. Pharmacol Res. 2000; 42(5): 485-7.
Cohen A, Martin M, Mizanin J, Konkle OF, Schwartz E. Vision and hearing during deferoxamine therapy. J Pediatr. 1990; 117(2 Pt I): 326-30.
Cuda D, De Benedetto M, Leante M, Corvaglia E. The prevalence and evolution of hypoacusis in Cooley's disease Acta Otorhinolaryngol Ital. 1991; 11(5): 471-81.
De Espana R, Biurrun О, Lorente J, Valls J, Ortcu N, Traserra J. Ototoxicity of deferoxamine. An Otorrinolaringol Ibero Am. 1992; 19( 4): 341-7.
De Sanctis V, Pinamonti A, Di Palma A, Sprocati M, Atti G, Gamberini MR, Vullo C. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine. Eur J Pediatr. 1996; 155(5): 368-72.
Kontzoglou G, Koussi A, Economou M, Tsatra I, Perifanis V, Noussios G, Athanassiou-Metaxa M. Long term audiological evaluation of betathalassemic patients. Acta Otorhinolaryngol Belg. 2004; 58(2): 113-7.
Luzzato L et al. Increased suckling of parasitized erythrocytes as mechanism of resistance against malaria in the sickle-cell trait. Lancet, 1970, I :319.
Onerci M, Asian S, Gumruk F, Aksoy S, Bclgin E, Ozcelik T, Altay C. Audiologic and impedancemetric findings within thalassaemic patients. Int J Pediatr Otorhinolaryngol. 1994; 28(2-3): 167-72.
Sacco M, Meleleo D, Tricarico N, Greco Miani A, Serra E, Parlatorc L. Evaluation of desferrioxamine ototoxicity in thalasscmic patients. Follow-up over a 5-ycar period and results. Minerva Pcdiatr. 1994; 46(5): 225-30.
Лаборатория по молекулярна патология: бета-таласемия (OMIM 141900) СБАЛАГ "Майчин дом", Медицински университет - София; http://www.lmpbg.org/lib/dd1.htm
